Oncoguide ncc oncopanel system

Manufactured by Sysmex

Sourced in Japan

The OncoGuide NCC Oncopanel System is a comprehensive genomic profiling platform designed for cancer diagnostics. It utilizes next-generation sequencing technology to analyze multiple cancer-related genes simultaneously. The core function of this system is to provide detailed genetic information about a patient's tumor, which can assist healthcare professionals in making informed treatment decisions.

Automatically generated - may contain errors

Lab products found in correlation

Cobas egfr mutation test v2, by Roche (2 mentions) Foundationone cdx, by Foundation Medicine (1 mentions) Foundationone liquid cdx, by Foundation Medicine (1 mentions) Therascreen egfr rgq pcr kit, by Qiagen (1 mentions)

7 protocols using oncoguide ncc oncopanel system

Advanced BTC CGP Observational Study

Check if the same lab product or an alternative is used in the 5 most similar protocols

This study is a prospective multicenter observational study of CGP in patients with advanced BTC. All relevant institutional ethics review boards approved this study (312–64), which was performed according to the provisions of the Declaration of Helsinki. Written consent was obtained from all patients. Seventy-two patients with advanced BTC underwent CGP, paid for by public health insurance, using FoundationOne^® CDx genome profiling (F1CDx; Chugai Pharmaceutical, Tokyo, Japan), FoundationOne^® Liquid CDx genome profiling (F1LCDx; Chugai Pharmaceutical), and an OncoGuide™ NCC Oncopanel System (NCC Oncopanel, Sysmex Corporation, Kobe, Japan). Patients were recruited between August 2019 and January 2022. Clinical data, including OS and demographic information, were collected from medical records and patient interviews.

Takada K., Kubo T., Kikuchi J., Yoshida M., Murota A., Arihara Y., Nakamura H., Nagashima H., Tanabe H., Sugita S., Tanaka Y., Miura A., Ohhara Y., Ishiguro A., Yokouchi H., Kawamoto Y., Mizukami Y., Ohnishi H., Kinoshita I, & Sakurai A. (2022). Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: A prospective multicenter study. Frontiers in Oncology, 12, 988527.

+ Open protocol

+ Expand

Comprehensive Genomic Profiling in Japan

Check if the same lab product or an alternative is used in the 5 most similar protocols

We include CGP tests that were covered by National Health Insurance in Japan. At first, these were three CGP tests that were covered by National Health Insurance: OncoGuide NCC Oncopanel System (Sysmex Corporation), FoundationOne® CDx Cancer Genomic Profile (Chugai Pharmaceutical), and FoundationOne® Liquid CDx Cancer Genomic Profile (Chugai Pharmaceutical). Some other CGP tests were additionally covered by this insurance and therefore we then added these new CGP tests by revising the protocol.

Ando Y., Shimoi T., Sunami K., Okita N., Nakamura K., Shibata T., Fujiwara Y, & Yamamoto N. (2023). Progress report of a cross‐organ and biomarker‐based basket‐type clinical trial: BELIEVE Trial. Cancer Science, 115(2), 555-563.

+ Open protocol

+ Expand

EGFR mutation detection methods

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The diagnosis of EGFR mutation including exon 20 insertion was performed based on PCR-based methods (therascreen EGFR RGQ PCR Kit [Scorpion-ARMS technology]; QIAGEN, Hilden, Germany, and Cobas EGFR Mutation Test v2; Roche Diagnostics, Basel, Switzerland)^{21 (link),22 (link)} and next-generation sequencing (NGS) testing (OncoGuide NCC Oncopanel System, Sysmex, Kobe, Japan)^{23 (link)}.

Morita C., Yoshida T., Shirasawa M., Masuda K., Matsumoto Y., Shinno Y., Yagishita S., Okuma Y., Goto Y., Horinouchi H., Yamamoto N., Motoi N., Yatabe Y, & Ohe Y. (2021). Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Scientific Reports, 11, 18762.

+ Open protocol

+ Expand

Comprehensive Genomic Profiling Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Genomic data were also collected for patients who underwent tissue-based next-generation sequencing (NGS)-targeted gene panel analysis (FoundationOne® CDx [Chugai, Japan], or OncoGuide™ NCC Oncopanel System [Sysmex, Japan]).

Nakajima H., Harano K., Nakai T., Kusuhara S., Nakao T., Funasaka C., Kondoh C., Matsubara N., Naito Y., Hosono A., Mitsunaga S., Ishii G, & Mukohara T. (2022). Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer. The Breast : Official Journal of the European Society of Mastology, 61, 136-144.

+ Open protocol

+ Expand

Comprehensive Genomic Profiling for Cancer

Cited 5 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

CGP testing was performed using hybrid capture-based targeted DNA sequencing with FoundationOne CDx (Foundation Medicine), the OncoGuide NCC Oncopanel System (Sysmex Corporation), in-house NGS testing, or in blood-derived cell-free DNA with FoundationOne Liquid CDx (Foundation Medicine) or Guardant360 CDx (Guardant Health).^{4 (link),25 (link),26 (link),27 (link)} All patients were referred to the NCCH following discussion by regional molecular tumor boards (MTB) comprising medical oncologists, pediatric oncologists, pathologists, bioinformaticians, genome researchers, and genetic counselors.^{3 (link),28 (link)} In addition to reports from the inspection companies, the MTBs used reports containing clinical annotation and information regarding genotype-matched clinical trials from the Center for Cancer Genomics and Advanced Therapeutics national database.^{29 (link),30 (link)}

Uehara Y., Koyama T., Katsuya Y., Sato J., Sudo K., Kondo S., Yoshida T., Shoji H., Shimoi T., Yonemori K, & Yamamoto N. (2023). Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital. JAMA Network Open, 6(9), e2333188.

+ Open protocol

+ Expand

BELIEVE Trial: Expanded Access to CGP-Guided Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

It is a requirement that the CGPs used in this study are covered by the National Health Insurance or are conducted as AMCs (Fig. 1). Two CGPs, namely the OncoGuide™ NCC Oncopanel System (Sysmex Corporation) and the FoundationOne® CDx Cancer Genomic Profile (Chugai Pharmaceutical), are currently covered by the National Health Insurance as CGP tests. Tests performed under the AMC category, including the Todai Onco Panel and Oncomine™ Target Test System, were also eligible for this study (as of September 2022).Fig. 1

Trial schema of the BELIEVE trial. a If a CGP test is performed and some off-label drug is recommended for the patient, the patient would originally be considered for participation in a clinical trial for drug approval already underway. However, if there are no such clinical trials, the patient would be eligible for the BELIEVE trial. b Patients would be treated at any of the Designated Cancer Genomic Medicine Core Hospitals if they participate in this trial. Pharmaceutical companies provide the medicines free of charge and will receive efficacy and safety data from the trial

Ishimaru S., Shimoi T., Sunami K., Nakajima M., Ando Y., Okita N., Nakamura K., Shibata T., Fujiwara Y, & Yamamoto N. (2023). Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial. International Journal of Clinical Oncology, 29(2), 89-95.

+ Open protocol

+ Expand

Evaluating EGFR Mutation Detection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Common EGFR mutations, including exon 19 deletion and L858R mutation, were assessed using PCR-based methods (Therascreen EGFR RGQ PCR kit [Scorpion-ARMS technology]; QIAGEN, Hilden, Germany, and Cobas EGFR Mutation Test v2; Roche Diagnostics, Basel, Switzerland) and next-generation sequencing testing (Oncomine™ Dx Target Test; Life Technologies Corporation, Carlsbad, CA and OncoGuide NCC Oncopanel System; Sysmex, Kobe, Japan).

Tamura K., Yoshida T., Masuda K., Matsumoto Y., Shinno Y., Okuma Y., Goto Y., Horinouchi H., Yamamoto N, & Ohe Y. (2023). Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases. ESMO Open, 8(4), 101594.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!